ONLINE RESOURCES

ONLINE RESOURCE FIG 1: Consort Figure for Randomized Clinical Trial

ONLINE RESOURCE FIG 2 Comparison of Analysis for Primary Outcome Variable for Intent to Treat and Completers Groups

ONLINE RESOURCE FIG 2 Interaction between Treatment and Attention/Concentration Score at Baseline vs. Change from Baseline in BADDS Attention/Concentration Subscale

ONLINE RESOURCE FIG 2 LEGEND: Individuals with baseline BADDS Attention/Concentration subscale score of greater than 10 were significantly more likely to experience a reduction in severity of reported attention/concentration difficulties than those participants with a subscale score of less than 10 at baseline.

ONLINE RESOURCE FIG 3 Interaction Between Treatment and Pittsburgh Sleep Quality Index Score (PSQI) at Baseline vs. Change from Baseline in PSQI

ONLINE RESOURCE FIG 3 LEGEND: Individuals with a baseline PSQI score of >6 were more likely to experience a greater improvement in sleep quality with active versus placebo treatment.
55 Assessed for Eligibility

20 Excluded
- 16 Did Not Meet Inclusion Criteria
- 4 Decided Not to Participate

35 Women Randomized Trial A

- 17 Assigned to Receive LDX in Trial A
  - 17 Received LDX as Assigned
  - 1 Discontinued Intervention Due to Side Effects, 1 Due to Personal Issue

- 18 Assigned to Receive Placebo in Trial A
  - 18 Received Placebo as Assigned
  - 0 Discontinued Intervention

33 Women Randomized Trial B

- 18 Assigned to Receive LDX in Trial B
  - 18 Received LDX as Assigned
  - 0 Discontinued Intervention

- 15 Assigned to Receive Placebo in Trial B
  - 15 Received Placebo as Assigned
  - 1 Discontinued Intervention Due to Time Constraints

32 Women Included in Analyses
Supplemental Materials Table 1: Comparison of Analyses for Primary Outcome Variable for Intent to Treat (ITT) and Completers

<table>
<thead>
<tr>
<th>Outcome Measure</th>
<th>ITT Analysis</th>
<th>Completers Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Has to make the score</td>
<td>Mean Difference in Rank Score Between Groups</td>
<td>Main Effect p-value</td>
</tr>
<tr>
<td>BADDS Total Score</td>
<td>-13.0</td>
<td>0.0001</td>
</tr>
<tr>
<td>BADDS Subscale Scores</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organization &amp; Activation for Work</td>
<td>-7.9</td>
<td>0.0021</td>
</tr>
<tr>
<td>Attention and Concentration</td>
<td>-12.0</td>
<td>0.0008</td>
</tr>
<tr>
<td>Alertness, Effort and Processing Speed</td>
<td>-7.7</td>
<td>0.0253</td>
</tr>
<tr>
<td>Managing Affective Interference</td>
<td>-6.0</td>
<td>0.0677</td>
</tr>
<tr>
<td>Working Memory and Accessing Recall</td>
<td>-11.8</td>
<td>0.0004</td>
</tr>
</tbody>
</table>
Interaction between Treatment and Attention/Concentration Score at Baseline vs. Change from Baseline in BADDS Attention/Concentration Subscale

Average Change from Baseline in Attn/Conc Score

BADDS Attention/Concentration Subscale Score at Baseline

Treatment 1: Active  2: Placebo

≤10

>10
Interaction between Treatment and PSQI Score at Baseline vs. Change from Baseline in PSQI Score

Treatment
1: Active
2: Placebo

Average Change from Baseline in PSQI Score

PSQI Score at Baseline

<=6

>6